This experience is in line with an empirical dose escalation of 225Ac-PSMA-617 (a PSMA-targeted agent) that was discontinued due to xerostomia, but without reaching dose-limiting hematological toxicity up to 20 MBq (200kBq/kgBW) [21]. The gene discussed is FOLH1; the disease is xerostomia.